05 / K-ECO BIO 10 · PIPELINE
Products · services · technology rights ·
data · IP — multi-layered revenue
This is not a single-product business. VPMI-CM manufacturing IP, the product range, service protocols, data assets and the QL1–QL5 purification value ladder move together, capturing short-term cash flow and long-term platform optionality at once.
In plain words
The heart of GRBM's business is turning products into service protocols. Selling only products is a short-term transaction; designing them as services creates customer experience, data, return visits and subscription conversion at the same time, and the accumulated data becomes the next products and IP.
GRBM is an integrated monetization structure that turns natural plant resources into metabolomes with VPMI-CM and then repeatedly converts them into products, services, data and IP. So GRBM has the character of a food company, a wellness-service company, an ingredient-platform company, a digital-healthcare company and a long-term bio-candidate-material company all at once.
Today it starts with cash-generating products; tomorrow it grows into a data-driven manufacturing ecosystem that extends human health and longevity.
INVESTOR QUESTIONS
Four questions investors ask,
and GRBM's answers
| Question | GRBM's answer |
|---|---|
| Is revenue possible now? | GINSENG GRBM, the MFB, MFS, MFK, MPM and MCM ranges and Low and Middle Level services can create early cash flow |
| Is it scalable? | Asset-light expansion through central manufacturing, frozen logistics, franchises, hotels, hospitals and AI subscriptions |
| Is it defensible? | VPMI-CM, ingredient-specific metabolome fingerprints, the QL purification system and human application data raise barriers over time |
| Can regulatory risk be controlled? | The wellness and food track and the MHM-PI research and clinical track are separated and managed in stages |
| Axis | What investors look for | GRBM's components |
|---|---|---|
| Cash Flow | Is the business validated by early revenue and repeat purchases? | GINSENG GRBM, MFB cans, MFS smoothies, MFK salt-free kimchi, MCM cosmetics, Low Level Service |
| Scalability | Do products and services scale on the same process and data? | Central VPMI-CM manufacturing, ingredient combinations, QL1–QL5 purification, frozen logistics, hotel, franchise and partner expansion |
| Moat | Are there processes, data and IP that cannot easily be copied? | Metabolome fingerprints, quality markers, microbiome profiles, human application data, G-M12 markers |
| Optionality | Is there long-term bio value beyond consumer goods? | MHM-PI, QL5 high-purity candidates, research reference standards, co-research and licence-out |
FIVE REVENUE LAYERS
Five revenue layers,
designed at the same time
-
01
Input
Fresh plants, ginseng, kimchi ingredients, milk, eggs, fruits and vegetables — each ingredient's life information and metabolic precursors
-
02
Platform Process
VPMI-CM + Vital Probiotics + metabolic process + QL purification — accumulating pH stabilization, CFU, organic-acid, amino-acid and marker data
-
03
Monetization Output
B2C products, B2B ingredients, Bio Healthcare services, AI subscriptions, QL5 candidates — product standardization, quality control, licensing, R&D and data assets
| Layer | Revenue model | Core products and assets | Meaning for investors |
|---|---|---|---|
| 1. Core IP | Manufacturing rights, technology-use rights, process control | VPMI-CM, manufacturing SOPs, quality-control system | The company's core controlled asset — protection and standardization matter more than disclosure |
| 2. Product Revenue | B2C sales and repeat purchase | GRBM, PANAX GRBM, MFB, MFS, MFK, MPM, MCM | Early revenue and validation of market response |
| 3. B2B Ingredient | Ingredient supply, OEM/ODM, licensing | GRBM Base, Ginseng QL3–QL4, MPM powder, MCM ingredients | High margin, partner expansion, global distribution leverage |
| 4. Service Revenue | Franchise, hotel, resort and subscription services | Low, Middle, High and Holon Level Services | Turning products into service protocols to raise revenue per customer |
| 5. Data & Bio Optionality | Data assets, co-research, patents, QL5 | Human application data, G-M12, MHM-PI candidates | Long-term enterprise value and strategic expansion options |
The three revenue axes — products, services, and royalties and licensing — expand in parallel, not one after another.
PRODUCT · B2B
Products are the engine that draws customers in;
B2B is the lever of capital efficiency
Product revenue is not just B2C income but a product pull-through engine that draws customers into service protocols and subscriptions.
| Product line | Flagship product | Revenue position | Strategic role |
|---|---|---|---|
| GRBM Base | Single-plant metabolomes such as fleabane and matsutake | B2C base liquids and B2B ingredients | Building a plant-by-plant metabolome library |
| PANAX GRBM | GINSENG 5000mg, sea buckthorn berry | Premium concentrates, powders, service ingredients | Flagship cash cow and brand symbol |
| GRBM MFB | GINSENG 250ml can | High-frequency repeat-purchase drink | Mass-market validation and wider distribution |
| GRBM MFS | Cool Gut | Frozen functional smoothie | Entry product for gut-microbiome and personalized nutrition |
| GRBM MFK | Plant-lactobacilli salt-free kimchi | Care food, K-Metabolome | Low- and no-salt repositioning of the global kimchi market |
| GRBM MPM | Baby Growth Formula | Metabolic protein powder | Nutrition for infants, patients, seniors and sport |
| GRBM MCM | Skin Barrier Ritual Set | High-margin cosmeceutical | Fast commercialization and a K-Beauty touchpoint |
| GRBM MHM-PI | QL5 Precision Candidate Material | Research and candidate materials | Long-term IP and biotech optionality |
B2B is the key route to GRBM's capital efficiency. Instead of carrying every finished product and channel itself, the company provides ingredients, fractions, technology and data to partners, accelerating global expansion.
| B2B asset | Potential partners | Revenue model | Validation points |
|---|---|---|---|
| GRBM Base Ingredient | Food, health-food and beverage companies | Ingredient supply, co-development | Batch consistency, safety profile, functional markers |
| Ginseng QL3·QL4 Fraction | Premium nutrition and pharma R&D | High-margin ingredients, licensing | G-M12 markers, LC-MS profile, purity grade |
| MCM Cosmetic Base | K-Beauty OEM/ODM, global skin care | Ingredient supply, brand co-development | Skin safety, formulation stability, claim management |
| MPM Protein Matrix | Formula, patient-meal and sports nutrition | B2B powder, formula licensing | Amino-acid spectrum, allergy and digestive-burden management |
| Data·Protocol Package | Wellness centres, hotels, medical partners | Service licences, SOPs, training | Operational standardization, management of regulatory wording |
Today, cash-generating products;
tomorrow, a data-driven manufacturing ecosystem
A platform that turns biodiversity into products, services, recurring revenue, defensible IP and long-term bio-candidate options.
BIO HEALTHCARE 4-LEVEL SERVICE
Products into service protocols —
four levels of Bio Healthcare
| Level | Format | Programs | Meaning for investors |
|---|---|---|---|
| Low Level | Urban front-end service. Stores of about 165 m² with 8 recovery seats or rooms | About 2-hour Metabolic Rest Session, MFK, MFS, MFB and MPM intake, MCM spa and massage, memberships and product subscriptions | Consumer touchpoint and product-experience channel; franchisable SOPs |
| Middle Level | Hotel-integrated, asset-light premium program | 48-Hour Reset, 7-Day Alignment, 14-Day Deep Recovery | Higher spend per customer, biomarker data before and after, no large property ownership |
| High Level | Hospital-linked, resort-based supportive care | Advanced Recovery (2–4 weeks), Complex Metabolic Support (4–8 weeks), Clinical Observation (4–12 weeks), VIP Family Integrated Care | The clinical credibility layer; does not replace hospital treatment, but works with medical institutions to provide a recovery environment and metabolic supportive care |
| Holon Level | High-value subscription built on lifelong data | Holon Prime, Holon Elite, Holon Sovereign, Holon Family Office — regular tests, personalized GRBM, AI reports, dedicated managers, global frozen delivery | Recurring revenue, high revenue per customer, long-term data assets, platform lock-in |
Holon Level is the most investor-friendly layer. It is not a one-off sale but an AI Health Intelligence + Personalized Metabolome Manufacturing + Global Frozen Bio-Fulfillment model that regularly supplies personalized GRBM based on each customer's lifelong data. Details of each service are on Four-Level Bio Healthcare Service.
Service prices, operating assumptions and centre-level unit economics are internal assumption models for investor explanation and are provided as materials after an NDA.
DATA-COMPOUNDING MOAT
Long-term defensibility comes not from the number of products,
but from accumulated data
| Data category | Where it is collected | Contribution to enterprise value |
|---|---|---|
| Ingredient-specific metabolome fingerprints | Manufacturing process and QC | Product standardization, batch reproducibility, substitutability of ingredients |
| Quality and functional markers | QL3–QL5 separation and purification | B2B ingredient pricing, licensing, research credibility |
| Human application data | Low, Middle, High and Holon services | Customer response maps, publication, MHM-PI candidate discovery |
| Customer behaviour data | Stores, apps, subscriptions | Repurchase, upselling, optimizing product combinations |
| Regulatory evidence data | Testing, IRB, observational studies | Country entry strategies, risk control, strategic partnerships |
Because only we can make GRBM, the papers themselves become the most powerful promotion — disclosing, disease by disease, which plant and which GRBM were taken, how much and how, and what changed. Consumers read the papers and judge for themselves, and the findings spread through social media, the press and academic societies.
Read moreCloseGo-to-market roadmap, commercialization investment priorities, risk control and investment logic
Go-to-market roadmap
| Phase | Period | Main actions | Target indicators |
|---|---|---|---|
| Phase 1 · Korea Premium Validation | 0–12 months | Launch of GINSENG GRBM 50ml, MFB Ginseng cans and flagship MFK, MFS and MCM products; Low Level pilot | Price acceptance, repurchase rate, early safety and quality data |
| Phase 2 · Service Proof | 12–24 months | 1–3 Low Level stores, 1–2 Middle Level hotel partners, Holon VIP pilot | Store unit economics, hotel-program satisfaction, subscription conversion |
| Phase 3 · B2B & Franchise Expansion | 24–36 months | B2B ingredient supply, OEM/ODM, franchise SOPs, frozen logistics | B2B contracts, franchise model, gross margin by product |
| Phase 4 · High Level Flagship | 36–60 months | Hospital-linked, resort-based High Level Center; observational research registry | Revenue per customer, human application data, publication pipeline |
| Phase 5 · Global Platform | After 60 months | Asia VIP, family offices, global logistics hubs, QL5 and MHM-PI co-research | Subscribers by country, licence agreements, research pipeline |
Commercialization investment priorities
Commercialization funds are allocated under a milestone-based plan — to commercial validation and risk removal before technology development, and to production, quality and storage infrastructure before product promotion. Long-term enterprise value comes not from product ideas but from a sequential value ladder: a reproducible manufacturing base, standard quality control, service revenue, subscription data and QL5 candidate materials.
-
01
Production and storage infrastructure
VPMI-CM production equipment, GRBM standard metabolic tanks, a dedicated PANAX GRBM line, frozen and refrigerated storage, batch storage systems, cold-chain readiness — the step that lowers investment risk first
-
02
Standard quality-control system
pH, acidity, CFU, microbial profile, organic acids, free amino acids, ginsenoside markers, contamination indicators, heavy metals and pesticide residues; batch tracking and COA issuance — proving a "reproducible platform"
-
03
PANAX GRBM products and brand
50ml concentrate, MFB GINSENG 250ml can, powders and capsules, packaging and labelling, initial distribution channels — fast market entry and a regular subscriber base
-
04
Opening service centres
Low, Middle and High Level centres, training of specialists and nutrition staff, service SOPs, customer report systems — turning sales into service revenue, data and lock-in
-
05
Holon AI system and app
Personalized app, customer database, links to microbiome, blood, check-up and wearable data, personalized GRBM protocol recommendations, global frozen-delivery tracking
-
06
QL5 line and MHM-PI
QL5 purification equipment, HPLC and LC-MS analysis, high-purity candidate fractions, co-research with institutions, patents, papers and non-clinical preparation — the option that lifts long-term enterprise value
Risks and control structure
| Risk | Investor concern | Response |
|---|---|---|
| Treatment claims | Food and services being mistaken for medical practice | Products and Low, Middle and Holon services are described as wellness and metabolic support; treatment and diagnosis wording is prohibited |
| MHM-PI regulation | Confusion between injectables and drug candidates and the consumer track | QL5 and MHM-PI are separated into their own research, non-clinical, GMP, clinical and approval track |
| Data and privacy | Managing sensitive information at Holon Level | Consent-based collection, encryption, country-specific storage policies and human review |
| Quality reproducibility | Plant variability and batch deviation | Ingredient standards, VPMI-CM, QC markers, reproducibility validation over three or more batches |
| Operational scale-up | Quality variance across franchises, hotels and resorts | SOPs, training, central manufacturing and logistics, tiered partner governance |
| Reputation | Sensitivity of high-priced services and services for seriously ill clients | Eligibility assessment, medical partnership, emergency protocols, restraint in describing outcomes |
| Technology leakage | External leakage of the core process | Black-box management of VPMI-CM and a know-how system managed directly by the developer |
The core investment logic
- Platform-first, Product-provenValidated through the product range, but at its core a manufacturing platform combining VPMI-CM and data
- Near-term Cash Flow + Long-term OptionalityProducts and Low and Middle services create early revenue; Holon, QL5 and MHM-PI create long-term enterprise value
- Asset-light ExpansionCentral manufacturing and frozen logistics allow franchise, hotel and partner models that reduce capital expenditure
- Data-compounding MoatAs customer and ingredient data accumulate, product design, quality control, AI recommendation and candidate discovery grow stronger
- ESG & Nature-based SolutionA strong narrative: plant resources for the climate era, savings in water, pollution and cost, and building an eco-bio industrial ecosystem
- Strategic Platform ValueStrategic value for food, beverage, K-Beauty, digital health, personalized nutrition, bio-manufacturing and biotech companies alike
GRBM is not a simple consumer product. It is a future eco-bio platform that turns biodiversity into data, services, IP and bio-candidates.
Complete Proposal, Chapter 12 "GRBM Business Model"
Service revenue and operating indicators are internal assumption models for investor explanation, not confirmed revenue. Detailed materials are provided after an NDA.
PARTNERSHIP · INVESTMENT
The world's first true eco-bio platform technology —
we are looking for the one partner
After signing an NDA you can review the materials, then verify the original records and the process in person during on-site due diligence in Uljin, Gyeongsangbuk-do, Korea.